GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Royalty Pharma RPRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

68.77

+2.18%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$2.38bn

FY2016FY2025

Net income

$770.9m

FY2016FY2025

Free cash flow

$2.49bn

FY2016FY2025

Shareholders' equity

$6.48bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$2.38bn$2.26bn$2.35bn$2.24bn$2.29bn$2.12bn$1.81bn$1.79bn$1.60bn$1.88bn
Gross profit$2.38bn$2.26bn$2.35bn$2.24bn$2.29bn$2.12bn$1.81bn$1.79bn$1.60bn$1.88bn
Research and development$452.0m$2.0m$52.0m$177.1m$200.1m$26.3m$83.0m$392.6m$117.9m$91.0m
Operating income$1.56bn$1.29bn$1.61bn$307.1m$1.43bn$1.86bn$2.62bn$1.62bn$939.7m$722.9m
Net income$770.9m$859.0m$1.13bn$42.8m$619.7m$975.0m$2.35bn$1.38bn$1.21bn$565.9m
Diluted earnings per share1.381.461.890.081.022.516.673.893.752.28

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$19.62bn$18.22bn$16.38bn$16.81bn$17.52bn$21.10bn$12.45bn$11.37bn$11.37bn$10.48bn
Cash and short-term investments$637.5m$1.77bn$1.23bn$2.43bn$2.80bn$1.99bn$793.2m$2.39bn$1.38bn$1.67bn
Total liabilities$9.91bn$7.88bn$6.30bn$7.29bn$7.27bn$6.12bn$6.31bn$6.82bn$6.90bn$6.02bn
Debt$8.95bn$7.61bn$6.14bn$7.12bn$7.10bn$5.82bn$6.24bn$6.52bn$280.9m$172.7m
Shareholders' equity$6.48bn$6.95bn$6.53bn$5.63bn$10.25bn$14.97bn$6.11bn$4.49bn$4.46bn$4.45bn
Shares outstanding560m589m602m523m607m388m352m354m323m249m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$2.49bn$2.77bn$2.99bn$2.14bn$2.02bn$2.03bn$1.67bn$1.62bn$1.42bn−$15.6m
Capital spending——−$2.12bn−$2.04bn−$523,000−$2.20bn−$1.72bn−$269.6m−$2.29bn—
Free cash flow$2.49bn$2.77bn$872.3m$102.8m$2.02bn−$162.4m−$54.1m$1.35bn−$872.4m−$15.6m
Dividends paid−$378.3m−$376.5m−$358.3m−$333.3m−$285.2m−$397.0m−$739.3m−$814.4m−$735.2m—

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$674.1m$630.6m$622.0m$609.3m$578.7m$568.2m$593.6m$564.7m
Gross profit$405.9m$629.4m$622.0m$609.3m$578.7m$568.2m$593.6m$564.7m
Operating income$175.1m$632.5m$388.4m$499.8m$151.0m$534.2m$361.5m$735.1m
Net income$17.9m$295.0m$214.2m$288.2m$30.2m$238.3m$208.2m$544.0m
Diluted earnings per share0.030.530.380.520.050.430.350.92
Cash from operations$686.0m$760.0m$827.0m$702.0m$363.0m$596.0m$742.0m$703.0m
Capital spending———−$1.0m———−$832.0m
Free cash flow———$701.0m———−$129.0m
Total assets$19.82bn$19.82bn$19.62bn$19.35bn$18.32bn$17.61bn$18.22bn$18.04bn
Cash and short-term investments$837.0m$608.3m$637.5m$955.0m$1.49bn$1.82bn$1.77bn$1.76bn
Debt$8.96bn$8.96bn$8.95bn$8.95bn$8.00bn$7.62bn$7.61bn$7.61bn
Shareholders' equity$6.83bn$6.89bn$6.48bn$6.41bn$6.35bn$6.69bn$6.95bn$6.87bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%——
Operating margin65.6%57.1%68.3%13.7%62.5%87.6%——
Net margin32.4%37.9%48.2%1.9%27.1%45.9%——
Return on equity11.9%12.4%17.4%0.8%6.0%6.5%——
Return on assets3.9%4.7%6.9%0.3%3.5%4.6%——
Free cash flow yield——14.5%13.7%5.7%18.6%16.4%19.6%
Revenue growth5.1%-3.9%5.2%-2.3%7.9%17.0%——
Earnings growth-10.2%-24.3%2549.5%-93.1%-36.4%-58.5%——
Current ratio0.97x1.44x7.90x2.19x16.81x8.76x——
Debt to equity1.38x1.10x0.94x1.26x1.36x0.41x——
Equity ratio33.0%38.1%39.8%33.5%58.5%71.0%——
Interest coverage5.07x5.73x8.59x1.63x8.61x11.84x——
R&D as a share of sales19.0%0.1%2.2%7.9%8.7%1.2%——
Buybacks as a share of market value5.0%2.2%-15.2%13.9%-56.4%-10.2%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue2.1%2.3%3.7%
Operating income71.9%-3.5%7.0%
Net income162.1%-4.6%2.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%100.0%100.0%100.0%
Operating margin61.4%51.6%59.0%65.9%
Net margin35.1%30.4%32.3%46.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings28.117.514.9482.239.019.9
Price to sales9.16.67.29.210.69.2

Market value over time

30 Jun 2020 to 22 Sept 2026, in USD

$17.19bn$32.59bn

Share price return

Finished calendar years

202520242023202220212020
Return57%-12%-30%3%-16%4%

Dividends and splits

Per share, in the currency the company pays

Paid for 6 years. Last went ex-dividend on 13 Nov 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Paid in the year0.940.880.840.800.760.680.30

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.